Neoadjuvant Therapy: A New Idea in Multidisciplinary Intervention for High-Risk Thyroid Cancers
- 1 January 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Clinical Thyroidology
- Vol. 35 (1)
- https://doi.org/10.1089/ct.2023;35.27-30
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Comparison of prognosis between neoadjuvant imatinib and upfront surgery for GIST: A systematic review and meta-analysisFrontiers in Pharmacology, 2022
- Apatinib vs Placebo in Patients With Locally Advanced or Metastatic, Radioactive Iodine–Refractory Differentiated Thyroid CancerJAMA Oncology, 2021
- The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical TrialThyroid®, 2021
- Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2020
- Overall Survival of Papillary Thyroid Carcinoma Patients: A Single‐Institution Long‐Term Follow‐Up of 5897 PatientsWorld Journal of Surgery, 2018
- Operative management of locally advanced, differentiated thyroid cancerSurgery, 2016
- RECIST 1.1—Update and clarification: From the RECIST committeeEuropean Journal of Cancer, 2016
- Tyrosine-kinase inhibitors to treat radioiodine-refracted, metastatic, or recurred and progressive differentiated thyroid carcinoma [Review]Endocrine Journal, 2016
- Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With SurvivalAnnals of Surgery, 2014